BioNTech SE (BNTX)
87.51
+1.65
(+1.92%)
USD |
NASDAQ |
Nov 06, 16:00
87.57
+0.06
(+0.07%)
After-Hours: 20:00
BioNTech Cash from Investing (Quarterly) : 922.53M for Sept. 30, 2026
Cash from Investing (Quarterly) Chart
Historical Cash from Investing (Quarterly) Data
| Date | Value |
|---|---|
| September 30, 2026 | 922.53M |
| June 30, 2026 | -118.82M |
| March 31, 2026 | 3.101B |
| December 31, 2025 | -3.086B |
| September 30, 2025 | -994.84M |
| June 30, 2025 | -27.66M |
| March 31, 2025 | 1.312B |
| December 31, 2024 | 649.24M |
| September 30, 2024 | -162.62M |
| June 30, 2024 | -248.84M |
| March 31, 2024 | -2.501B |
| December 31, 2023 | -2.835B |
| September 30, 2023 | -1.353B |
| June 30, 2023 | -2.491B |
| Date | Value |
|---|---|
| March 31, 2023 | -789.04M |
| December 31, 2022 | -170.64M |
| September 30, 2022 | -95.10M |
| June 30, 2022 | -93.49M |
| March 31, 2022 | 322.41M |
| December 31, 2021 | -551.06M |
| September 30, 2021 | -48.80M |
| June 30, 2021 | -35.88M |
| March 31, 2021 | -34.09M |
| December 31, 2020 | -115.54M |
| September 30, 2020 | -23.24M |
| June 30, 2020 | -10.61M |
| March 31, 2020 | -16.45M |
Cash From Investing Definition
Represents the net cash flow from the company's investing activities. Investing activities represent the movement in the company's long-term assets.
Cash from Investing (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Cash from Investing (Quarterly) Benchmarks
| Biodexa Pharmaceuticals Plc | -- |
| Moderna, Inc. | 329.00M |
| Mereo BioPharma Group Plc | -0.0004M |
| NuCana Plc | -0.0453M |
| Immatics NV | -9.277M |
Cash from Investing (Quarterly) Related Metrics
| Cash from Operations (Quarterly) | -148.25M |
| Cash from Financing (Quarterly) | -269.92M |
| Free Cash Flow | -563.78M |
| Free Cash Flow Per Share (Quarterly) | -0.8062 |
| Free Cash Flow to Equity (Quarterly) | -418.70M |
| Free Cash Flow to Firm (Quarterly) | -200.42M |
| Free Cash Flow Yield | -2.57% |